NuCana plc Presents Data on NUC-7738 and PD-1 Inhibitors at ESMO Congress 2025

NuCana plc announced the presentation of data on a new model system investigating the synergistic effects of NUC-7738 and PD-1 inhibition in primary organoids derived from patients with renal cell carcinoma at the European Society for Medical Oncology (ESMO) Congress 2025. The data revealed that NUC-7738 enhances the effectiveness of PD-1 inhibitors, resulting in increased tumor cell killing. This combinatorial approach may offer a new option for cancers that no longer respond to anti-PD-1 therapy. The data reinforces the mechanism of action for NUC-7738 observed in the ongoing Phase 1/2 NuTide:701 clinical study, which has demonstrated a favorable safety profile, meaningful tumor volume reduction, and prolonged progression-free survival in patients with PD-1 inhibitor refractory and resistant metastatic melanoma. Based on the initial data, regulators have approved the expansion of the study to recruit an additional 28 patients with PD-1 inhibitor-resistant melanoma.